3 part Hematology Analyzers

Hematology Analyzers Market Outlook

The global hematology analyzers market is projected to reach approximately USD 3.8 billion by 2035, expanding at a CAGR of around 5.6% during the forecast period from 2025 to 2035. The increasing prevalence of blood-related disorders such as anemia, leukemia, and other hematological conditions is a significant growth factor contributing to this upward trajectory. Additionally, the rising demand for early and precise diagnosis plays a crucial role in market expansion, as healthcare providers increasingly emphasize high-quality patient care. Advancements in technology, such as the integration of automation and artificial intelligence in hematology analyzers, are enhancing diagnostic capabilities and improving operational efficiency. Furthermore, the growing number of clinical laboratories and diagnostic centers worldwide is expected to drive the market for hematology analyzers significantly.

Growth Factor of the Market

The hematology analyzers market is primarily fueled by the increasing prevalence of chronic diseases and the growing aging population, which often require regular blood tests and monitoring. The rise in health awareness and the emphasis on preventive healthcare are driving the demand for accurate and rapid diagnostic solutions. Furthermore, technological advancements such as the development of point-of-care testing (POCT) hematology analyzers have made it possible to conduct tests in various healthcare settings, thereby increasing access to testing and diagnostics. Additionally, the automation of laboratory processes helps reduce human errors and improves turnaround times for test results, which is vital in critical patient care situations. The growing number of partnerships and collaborations between key stakeholders in the healthcare ecosystem also supports market growth by facilitating innovation and the introduction of new products. Finally, government initiatives aimed at improving healthcare accessibility and funding for research and development in hematology diagnostics are further propelling the market forward.

Key Highlights of the Market

• The hematology analyzers market is projected to grow at a CAGR of 5.6% from 2025 to 2035.
• Technological advancements, including automation and AI integration, are driving product innovation.
• Increasing prevalence of blood-related disorders necessitates improved diagnostic solutions.
• Point-of-care testing is gaining traction, enhancing accessibility to diagnostics.
• Government initiatives aimed at improving healthcare infrastructure are bolstering market growth.

By Product Type

3-Part Hematology Analyzers:

The 3-part hematology analyzers are among the most commonly used devices in clinical laboratories for routine blood analyses. These analyzers provide essential parameters such as red blood cell (RBC) count, white blood cell (WBC) count, and hemoglobin concentration, making them vital in primary care settings. Their simplicity and cost-effectiveness are significant advantages, contributing to their widespread adoption. The ease of operation and minimal training required for laboratory personnel further enhance their appeal. While these analyzers may not provide the comprehensive data found in more advanced models, they are suitable for basic screening and are particularly valuable in smaller facilities with limited testing needs.

5-Part Hematology Analyzers:

5-part hematology analyzers offer a more detailed differentiation of white blood cells than their 3-part counterparts. These devices are capable of analyzing five distinct populations of WBCs, thereby providing a more comprehensive view of a patient's hematological status. This capability is crucial for diagnosing various conditions, including infections and hematological malignancies. As a result, these analyzers are increasingly favored in mid-sized hospitals and diagnostic laboratories that require a balance between performance and cost. With the advent of automation and digital interfaces, the efficiency of 5-part analyzers has improved, leading to faster turnaround times and reduced manual errors in test results.

6-Part Hematology Analyzers:

6-part hematology analyzers go a step further by offering even more advanced capabilities for white blood cell differentiation, including the identification of immature granulocytes. These devices are particularly beneficial in specialized settings such as oncology and research laboratories, where a deeper understanding of blood cell morphology is crucial. Their advanced technology allows for more accurate and nuanced results, making them indispensable tools for clinicians managing complex cases. Although they are typically more expensive than 3-part and 5-part analyzers, the added value they offer in terms of diagnostic precision justifies the cost, leading to their increasing adoption in advanced healthcare facilities.

Point-of-Care Hematology Analyzers:

Point-of-care (POC) hematology analyzers represent a transformative advancement in the field of diagnostics, allowing tests to be conducted at or near the site of patient care. This accessibility is particularly beneficial in emergency departments, remote clinics, and during patient transport. The rapid results provided by these devices facilitate timely clinical decisions, which can be critical in emergency situations. With rising demand for immediate test results and enhanced patient monitoring, the acceptance of POC hematology analyzers is rapidly growing. Furthermore, their user-friendly design and portability make them suitable for a wide range of healthcare settings, including home healthcare and field operations.

Fully Automated Hematology Analyzers:

Fully automated hematology analyzers are the pinnacle of technology in hematology diagnostics, integrating various functions into a single device. These analyzers can process a high volume of samples with minimal human intervention, significantly increasing laboratory productivity. Their automation reduces the likelihood of human error and enhances the consistency of results, which is essential for accurate diagnostics. Additionally, many of these devices come equipped with advanced software for data management and analysis, allowing healthcare providers to track patient trends over time. While the initial investment may be substantial, the long-term benefits in efficiency and diagnostic accuracy make fully automated systems increasingly popular in large hospitals and reference laboratories.

By Application

Hospitals:

Hospitals are the primary users of hematology analyzers, as they require efficient and accurate blood testing capabilities for a vast patient population. Hematology analyzers in hospital settings play a crucial role in diagnosing various conditions, monitoring patient health, and guiding treatment decisions. The need for timely results in emergency situations drives the demand for advanced analyzers that can deliver accurate data quickly. Furthermore, hospitals are increasingly adopting fully automated systems to optimize laboratory workflows and improve patient care outcomes. The integration of hematology analyzers with hospital information systems also enhances data management, facilitating seamless communication between departments and improving the overall efficiency of patient care.

Diagnostic Laboratories:

Diagnostic laboratories serve a pivotal role in the healthcare ecosystem by providing specialized testing services to hospitals, clinics, and physicians. The demand for hematology analyzers in these laboratories is consistently high, as they perform numerous blood tests daily. The need for high throughput, accuracy, and reliability is crucial in this setting, as diagnostic laboratories aim to provide timely results for a variety of blood disorders. As a result, the market for hematology analyzers within diagnostic laboratories is witnessing significant growth, especially with the increasing trend towards automation and the need for high-quality diagnostic services. Advanced features such as connectivity to laboratory management systems enhance operational efficiency, making diagnostic laboratories a key sector for hematology analyzer manufacturers.

Research Institutes:

Research institutes utilize hematology analyzers for various studies and clinical trials, often focusing on the development of new diagnostic methods and treatments for blood diseases. The need for precision and advanced analytical capabilities is paramount in research settings, as the outcomes of studies can have significant implications for medical science. Hematology analyzers in research institutes aid in the exploration of blood cell biology and the pathophysiology of disorders, thereby contributing to advancements in clinical medicine. The growing investment in biomedical research and the increasing focus on personalized medicine are expected to drive the demand for hematology analyzers in these institutions, further solidifying their role in the innovation of healthcare solutions.

Others:

This category encompasses various other applications, including veterinary clinics, military medical services, and educational institutions. In veterinary settings, hematology analyzers are employed to diagnose and manage blood disorders in animals, reflecting a growing awareness of animal health and welfare. Military medical services utilize these devices for rapid blood testing in field hospitals, where timely diagnostics can make a critical difference. Furthermore, educational institutions may use hematology analyzers in training programs for students pursuing careers in healthcare. The ongoing expansion of healthcare services and the increasing emphasis on diagnostics across various sectors contribute to the demand for hematology analyzers in these diverse applications.

By Distribution Channel

Direct Sales:

Direct sales channels represent a vital approach for manufacturers of hematology analyzers to engage with healthcare facilities, providing personalized service and support. This model allows manufacturers to build strong relationships with their clients, offering tailored solutions and immediate assistance when needed. Direct sales are particularly beneficial for large healthcare organizations that require customizable products and specialized service packages. Additionally, this approach facilitates better communication regarding product updates, training, and maintenance, ensuring that customers receive optimal value from their investments. As a result, direct sales channels are expected to remain a key component of the distribution strategy for hematology analyzer manufacturers.

Distributor Sales:

Distributor sales play a crucial role in the hematology analyzers market, enabling manufacturers to reach a wider customer base, including small clinics, reference laboratories, and other healthcare facilities. Distributor partners often possess in-depth knowledge of local markets and can provide valuable insights into customer needs. They are responsible for marketing products, managing inventory, and providing after-sales support, which can significantly enhance customer experience. The reliance on distributor networks allows manufacturers to focus on product development while ensuring that customers have access to their devices and services. As the demand for hematology analyzers grows globally, distributor sales channels are expected to expand, further facilitating market penetration.

By User

Hospitals:

Hospitals are the primary users of hematology analyzers, as they require efficient and accurate blood testing capabilities for a vast patient population. Hematology analyzers in hospital settings play a crucial role in diagnosing various conditions, monitoring patient health, and guiding treatment decisions. The need for timely results in emergency situations drives the demand for advanced analyzers that can deliver accurate data quickly. Furthermore, hospitals are increasingly adopting fully automated systems to optimize laboratory workflows and improve patient care outcomes. The integration of hematology analyzers with hospital information systems also enhances data management, facilitating seamless communication between departments and improving the overall efficiency of patient care.

Clinics:

Clinics, including primary care and specialized medical practices, utilize hematology analyzers to perform routine blood tests and monitor patients' health. The growing trend of point-of-care testing has made hematology analyzers more accessible to clinics, enabling timely diagnosis and treatment decisions. These devices are essential for managing chronic conditions, where regular blood monitoring is critical for patient outcomes. The adoption of more compact and user-friendly analyzers allows clinics to perform in-house testing, reducing the need for referrals to external laboratories and minimizing delays in patient care. As the healthcare landscape evolves, clinics increasingly recognize the value of hematology analyzers for enhancing patient management and improving operational efficiencies.

Diagnostic Centers:

Diagnostic centers focus exclusively on laboratory testing services, making them significant users of hematology analyzers. These facilities require high-throughput analyzers to accommodate the large volume of tests conducted daily, ensuring rapid report generation for healthcare providers. The evolution of diagnostic centers towards automation and integrated systems enhances their operational efficiency and improves test accuracy. With the increased emphasis on quality assurance and standardized testing processes, diagnostic centers are turning to advanced hematology analyzers that meet rigorous regulatory requirements. This sector is poised for growth as the demand for laboratory testing continues to rise, highlighting the critical role of hematology analyzers in delivering timely and accurate diagnostics.

Research Institutes:

Research institutes utilize hematology analyzers for various studies and clinical trials, often focusing on the development of new diagnostic methods and treatments for blood diseases. The need for precision and advanced analytical capabilities is paramount in research settings, as the outcomes of studies can have significant implications for medical science. Hematology analyzers in research institutes aid in exploring blood cell biology and the pathophysiology of disorders, thereby contributing to advancements in clinical medicine. The growing investment in biomedical research and the increasing focus on personalized medicine are expected to drive the demand for hematology analyzers in these institutions, further solidifying their role in the innovation of healthcare solutions.

By Region

North America dominates the global hematology analyzers market, valued at approximately USD 1.2 billion in 2025 and expected to grow at a CAGR of 5.1% through 2035. The region benefits from a well-established healthcare infrastructure, increased prevalence of blood disorders, and the presence of leading manufacturers. The integration of advanced technologies and the emphasis on research and development further contribute to market expansion in North America. Additionally, favorable reimbursement policies and high healthcare expenditure support the adoption of innovative hematology solutions. The region's focus on improving patient outcomes through accurate and timely diagnostics positions it as a leader in the hematology analyzers market.

Europe is anticipated to hold a significant share of the hematology analyzers market, projected to reach around USD 1 billion by 2035. This growth is driven by the increasing demand for advanced diagnostic solutions and the rising incidence of blood-related diseases across the region. The European Union's initiatives to enhance healthcare access and improve laboratory services also play a crucial role in shaping market dynamics. Moreover, collaboration among key stakeholders in the healthcare industry facilitates the introduction of new technologies and products. As healthcare providers in Europe focus on optimizing patient care through accurate diagnostics, the demand for hematology analyzers is expected to continue rising in this region.

Opportunities

The hematology analyzers market presents numerous opportunities for growth driven by technological advancements and increasing healthcare investments. The rise of point-of-care testing (POCT) is revolutionizing blood diagnostics, providing immediate results that enhance patient management in various settings, from hospitals to outpatient clinics. This trend opens up new avenues for manufacturers to develop portable and user-friendly hematology analyzers that cater to the needs of diverse healthcare environments. Moreover, the growing emphasis on personalized medicine and precision diagnostics is prompting the development of advanced analyzers capable of providing detailed insights into patients' hematological health. Manufacturers can leverage these opportunities by investing in research and development to innovate products that meet the evolving demands of healthcare providers.

Another significant opportunity lies in expanding the geographical reach of hematology analyzers, particularly in emerging markets. With rising healthcare expenditures and increasing awareness of the importance of early diagnosis and treatment, countries in Asia Pacific and Latin America are poised for substantial growth. Manufacturers can explore partnerships and collaborations with local distributors to penetrate these markets effectively. Additionally, the increasing prevalence of chronic diseases necessitates improved diagnostic capabilities, creating a favorable environment for the adoption of hematology analyzers. By aligning their strategies with the needs of emerging markets and investing in localized solutions, companies can capitalize on the growth potential presented in these regions.

Threats

One of the primary threats to the hematology analyzers market is the increasing competition among manufacturers, which can lead to price erosion and reduced profit margins. As more companies enter the market and existing players expand their product lines, the pressure to remain competitive intensifies. This competition often forces manufacturers to lower prices, which can impact their ability to invest in research and development for innovative products. Furthermore, the rapid pace of technological advancements poses a challenge for companies to keep up, as outdated equipment may become obsolete, leading to potential market share loss. The need for continuous innovation and adaptation to changing market dynamics is crucial for manufacturers to maintain their competitive edge.

Another significant restrainer for the growth of the hematology analyzers market is the stringent regulatory framework imposed by governing bodies. Obtaining regulatory approvals for new devices can be a lengthy and complex process, which may delay the introduction of innovative products to the market. Additionally, compliance with quality standards and safety regulations requires considerable investment from manufacturers, potentially limiting their resources for product development. This regulatory environment can deter new entrants from exploring the market, limiting competition and slowing innovation. As healthcare providers increasingly demand advanced and reliable diagnostic solutions, manufacturers must navigate these regulatory challenges effectively to capitalize on market opportunities.

Competitor Outlook

• Abbott Laboratories
• Beckman Coulter, a subsidiary of Danaher Corporation
• Sysmex Corporation
• Siemens Healthineers
• Horiba Medical
• Roche Diagnostics
• Mindray Medical International Limited
• Thermo Fisher Scientific
• Guangzhou Wondfo Biotech Co., Ltd.
• Nihon Kohden Corporation
• Ortho Clinical Diagnostics
• ProSciTech Pty Ltd
• Chembio Diagnostic Systems, Inc.
• Hematologic Technologies, Inc.
• Grifols S.A.

The competitive landscape of the hematology analyzers market is characterized by the presence of several key players, each striving to innovate and capture market share. Major companies are heavily investing in research and development to introduce cutting-edge technologies, such as fully automated systems and advanced point-of-care devices. This focus on innovation not only enhances their product offerings but also positions them as leaders in the market. Strategic partnerships and collaborations with healthcare institutions and research organizations are also prevalent among these companies, enabling them to leverage local expertise and expand their reach in emerging markets. Additionally, companies are increasingly adopting marketing strategies that emphasize the benefits of their products to healthcare providers, highlighting their commitment to improving patient outcomes through accurate and timely diagnostics.

Abbott Laboratories, one of the leading players in the hematology analyzers market, excels in creating innovative diagnostic solutions that cater to diverse healthcare needs. Their commitment to research and development has enabled them to launch advanced hematology analyzers that integrate automation and artificial intelligence, enhancing diagnostic accuracy and efficiency. The company's strong presence in both developed and emerging markets positions it well for future growth, as it continues to meet the evolving demands of healthcare professionals. Similarly, Sysmex Corporation is renowned for its comprehensive range of hematology analyzers, known for their reliability and precision. Sysmex's focus on technological advancements and its extensive global distribution network contribute to its sustained market success.

Another significant player, Beckman Coulter, a subsidiary of Danaher Corporation, offers a diverse portfolio of hematology analyzers, including fully automated systems designed for high-throughput testing. The company's emphasis on quality and customer satisfaction has earned it a loyal customer base across various healthcare settings. Additionally, Siemens Healthineers is recognized for its commitment to innovation in medical diagnostics, including hematology analyzers. The company's investments in advanced technologies, such as digitalization and connectivity, provide healthcare providers with solutions that enhance laboratory efficiency and patient care. As these major companies continue to innovate and adapt to changing market demands, they will play a crucial role in shaping the future of the hematology analyzers market.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Grifols S.A.
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 Horiba Medical
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 Roche Diagnostics
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 ProSciTech Pty Ltd
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Sysmex Corporation
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Abbott Laboratories
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Siemens Healthineers
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Nihon Kohden Corporation
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Thermo Fisher Scientific
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Ortho Clinical Diagnostics
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Hematologic Technologies, Inc.
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Chembio Diagnostic Systems, Inc.
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Guangzhou Wondfo Biotech Co., Ltd.
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Mindray Medical International Limited
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Beckman Coulter, a subsidiary of Danaher Corporation
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 3 part Hematology Analyzers Market, By User
    • 6.1.1 Hospitals
    • 6.1.2 Clinics
    • 6.1.3 Diagnostic Centers
    • 6.1.4 Research Institutes
  • 6.2 3 part Hematology Analyzers Market, By Application
    • 6.2.1 Hospitals
    • 6.2.2 Diagnostic Laboratories
    • 6.2.3 Research Institutes
    • 6.2.4 Others
  • 6.3 3 part Hematology Analyzers Market, By Product Type
    • 6.3.1 3-Part Hematology Analyzers
    • 6.3.2 5-Part Hematology Analyzers
    • 6.3.3 6-Part Hematology Analyzers
    • 6.3.4 Point-of-Care Hematology Analyzers
    • 6.3.5 Fully Automated Hematology Analyzers
  • 6.4 3 part Hematology Analyzers Market, By Distribution Channel
    • 6.4.1 Direct Sales
    • 6.4.2 Distributor Sales

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Middle East & Africa - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 Middle East
      • 10.5.1.2 Africa
  • 10.6 3 part Hematology Analyzers Market by Region

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global 3 part Hematology Analyzers market is categorized based on

By Product Type

• 3-Part Hematology Analyzers
• 5-Part Hematology Analyzers
• 6-Part Hematology Analyzers
• Point-of-Care Hematology Analyzers
• Fully Automated Hematology Analyzers

By Application

• Hospitals
• Diagnostic Laboratories
• Research Institutes
• Others

By Distribution Channel

• Direct Sales
• Distributor Sales

By User

• Hospitals
• Clinics
• Diagnostic Centers
• Research Institutes

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Abbott Laboratories
• Beckman Coulter, a subsidiary of Danaher Corporation
• Sysmex Corporation
• Siemens Healthineers
• Horiba Medical
• Roche Diagnostics
• Mindray Medical International Limited
• Thermo Fisher Scientific
• Guangzhou Wondfo Biotech Co., Ltd.
• Nihon Kohden Corporation
• Ortho Clinical Diagnostics
• ProSciTech Pty Ltd
• Chembio Diagnostic Systems, Inc.
• Hematologic Technologies, Inc.
• Grifols S.A.